At a glance
- Originator Aventis
- Class Antiallergics; Antiasthmatics; Piperidines; Pyrrolidines
- Mechanism of Action Neurokinin 1 antagonists; Neurokinin 2 antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 06 Jun 1997 Discontinued-Preclinical for Asthma in USA (Unknown route)
- 08 Aug 1996 Preclinical development for Asthma in USA (Unknown route)